Skip to main content

Abhi Jain

Analyst

AJB Capital

Equibles does not estimate personal net worth.

About Abhi Jain

Abhi Jain is recorded as Analyst at AJB Capital. Abhi Jain has spoken on 3 earnings calls across 3 companies, most recently for Sejal Glass Limited on October 19, 2026. Those appearances were for Sejal Glass Limited, Marksans Pharma Limited and Caplin Point Laboratories Limited. The companies whose calls Abhi Jain spoke on are classified in the Industrials and Healthcare sectors.

Abhi Jain on recent calls

“So, congratulations on a good set of numbers. My first question is that, you know, I've been tracking your business, and you have always been outperforming whatever you've guided for.”
Analyst — AJB Capital, Earnings Call for the Quarter Ended September 30, 2026 ·
“My first question is on capital allocation. So I'm on slide 28, and I think the ROE and ROCs have obviously fallen in the last few years. And close to all, we have 1,050 crores, 1,050 crores of cash.”
Analyst — AJB Capital, Earnings Call ·
“Good to see you as the growth rate is maintained and you're on track to achieving your long-term goals. So, congratulations on that. I have two questions. First, I wanted to discuss the rest of the world's profitability on the PPP level.”
Analyst — AJB Capital, Earnings Call for the Quarter Ended June 30, 2026 ·

Affiliation history

  • AJB Capital

    Analyst

    Transcript header (unverified)

    Current

Company network

Sejal Glass Limited

Building Products & Equipment · Industrials

1 appearance Latest appearance 2026-10-19

Marksans Pharma Limited

Drug Manufacturers - General · Healthcare

1 appearance Latest appearance 2026-08-13

Caplin Point Laboratories Limited

Drug Manufacturers - Specialty & Generic · Healthcare

1 appearance Latest appearance 2026-08-12

Recent activity

  • Earnings call

    Earnings Call for the Quarter Ended September 30, 2026

    Sejal Glass Limited

  • Earnings call

    Earnings Call

    Marksans Pharma Limited

  • Earnings call

    Earnings Call for the Quarter Ended June 30, 2026

    Caplin Point Laboratories Limited